Lineage Cell Therapeutics, Inc. (LCTX)
NYSE: LCTX · Biological Products, (No Diagnostic Substances) · Carlsbad, CA · filing with the SEC since 1996
Who owns Lineage Cell Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
Neal C. Bradsher holds 23.1% of Common shares, as its SCHEDULE 13D/A filed Nov 14, 2025 says.
Directors and officers
9
report now, of 27 people on the record since 2006. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
Neal C. Bradsher
SCHEDULE 13D/A · filed Nov 14, 2025 · Common shares · 24.5% in Jan 28, 2025
Blackrock, Inc.
SCHEDULE 13G · filed Jul 29, 2026 · Common Stock · 1% in Jul 17, 2025
Chernett Jorey
SCHEDULE 13G · filed Sep 26, 2025 · Common
What LCTX reports owning in othersstakes of 5% or more, and other ties
Other ties the annual report names
Broadwood Partners, L.P
An entity · legal entity · owns, named in the 10-K filed Mar 5, 2026
H.C. Wainwright & Co., LLC
An entity · legal entity · owns, named in the 10-K filed Mar 5, 2026
2 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 5, 2026.
Insider tradesForm 4
0sales
1purchases
0sales on a scheduled plan
0people selling
$0sold, in dollars
$0bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window1 of 29 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Culley Brian M | President and CEO | 0 | $0 | 0 | 1 | $0 |